Guardant Health Inc., a leader in precision oncology, announced the commencement of patient enrollment in the National Cancer Institute's $(NCI)$ Vanguard Study. This study evaluates Guardant Health's Shield Multi-Cancer Detection $(MCD)$ test, which is under review by the U.S. Food and Drug Administration (FDA) as part of the NCI's investigational device exemption $(IDE)$. The Vanguard Study, a critical step in cancer detection research, aims to enroll up to 24,000 participants to assess the feasibility of using MCD tests in future trials. Conducted by the Cancer Screening Research network, it seeks to determine the effectiveness of these tests in early cancer detection and reducing cancer mortality.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.